New Test Has Potential to Eliminate Need for Invasive Womb Cancer Exams

The development of a groundbreaking blood test for womb cancer, known as the PinPoint test, could pave the way for quicker diagnosis and eliminate the need for thousands of women to undergo invasive exams, recent studies suggest.

Womb cancer ranks as the fourth most prevalent cancer among women in the UK, recording approximately 9,700 new cases annually. Despite this, the number of women referred for transvaginal ultrasound scans to detect the disease exceeds 90,000 per year.

Scientists have now discovered that the new PinPoint blood test could potentially alleviate the need for many of these women to endure the intrusive procedure while also providing a more prompt diagnosis for those diagnosed with the disease.

The PinPoint test employs artificial intelligence to scrutinize markers in the blood to assess a patient’s risk of cancer. In a trial involving 16,481 women, including 2,953 with suspected cancer, the test demonstrated a 99% accuracy rate in diagnosing gynecological cancers and excluding their presence. The trial was conducted at multiple hospitals throughout Yorkshire, England.

“Speedy diagnosis of high-risk patients could lead to earlier-stage detection and a better diagnostic experience. In contrast, low-risk patients may be able to avoid unnecessary invasive cancer testing,” the study’s authors noted. They also emphasized the swift deployability of the PinPoint test’s software, stating it could be rolled out without the necessity for additional hardware.

Plans for further research on this promising new test for womb cancer are underway.

Photo Credit: Gabriel Silverio